Chemo options, with or without nivolumab, for HER2-negative stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-negative stomach/food-pipe junction/esophagus cancer confirmed on pathology, and you know your PD-L1 score (CPS).
- Your cancer is advanced and cannot be removed with surgery (unresectable) or has spread (metastatic).
- You have not had chemotherapy for the advanced/metastatic setting (prior chemo is allowed only if finished at least 1 year ago).
- Your scans show measurable disease, or your doctors can still track the cancer in an “evaluable” way.
- Your body needs to work well enough for treatment: age 18+, good daily functioning (ECOG 0–1), and certain blood counts and organ tests (kidney/liver) within required limits.
- If you may receive nivolumab: no recent serious autoimmune disease requiring stronger medicines, no recent immune-suppressing steroid use, no steroid-needed lung inflammation from prior immune therapy, and no prior immune therapy stopped permanently for immune side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
This Phase 2 trial tests whether a combination of chemo drugs (oxaliplatin and liposomal irinotecan) plus trastuzumab works better for people with advanced stomach or esophagus adenocarcinoma that has specific tumor markers (HER2 and PDL1). It may help shrink tumors and improve control of the cancer in people who have not had prior treatment for advanced disease.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
This Phase 2 trial tests adding chemotherapy plus trastuzumab and toripalimab around the time of surgery for HER2-positive, locally advanced stomach or esophagus-stomach junction cancer. It aims to shrink the cancer and reduce the chance it comes back by attacking it through more than one pathway.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
Hear when a new Advanced Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.